[12, 76–78] In a large randomised, prospective, placebo-controlled trial with high-dose
pravastatin (which, in particular, does not undergo P450 metabolism) in hypercholesterolaemic patients with compensated liver disease due to mostly non-alcoholic steatohepatitis or HCV, the cumulative risk of doubling an elevated baseline ALT value over 36 weeks was in fact lower in the pravastatin-treated group compared with untreated controls (7.5% vs. 12.5%).